Diagnostics News and Research RSS Feed - Diagnostics News and Research

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

The international outbreak of Ebola in 2014 serves as a reminder for the need to be proactive in preparing for the rapid spread of any newly emerging or re-emerging infectious disease. IDRI today announces it has received $4 million in funding from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to facilitate pandemic influenza preparedness in developing countries. [More]
New NIH grant to support development of rapid method for diagnosing mucormycosis

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists. [More]
Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Quad Technologies Inc (“Quad”), developer of a novel separation technology, has formally announced its entry into the cell separation market. [More]
TNF signaling molecule triggers Crohn's disease, ulcerative colitis

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. [More]
POCARED Diagnostics announces closure of another $15M in funding

POCARED Diagnostics announces closure of another $15M in funding

POCARED Diagnostics Ltd. is an Israeli-based Diagnostics and Pre-analytical technology manufacturer with offices in the United States announced they have closed another $15 Million in funding. [More]
ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

Arizona State University will host a premiere opportunity to engage and mingle with luminaries in the burgeoning field of evolutionary medicine, a new interdisciplinary approach that is becoming an essential perspective in our view of disease, today's medical practice and the worldwide impact on public health as it hosts the Inaugural International Society for Evolution, Medicine & Public Health Meeting, March 19-21, 2015 in Tempe, Arizona. [More]
UMHS opens Massey Emergency Critical Care Center

UMHS opens Massey Emergency Critical Care Center

They come from highway accident scenes and nursing home beds, from factories and farm fields, from suburban homes, downtown sidewalks and small community hospitals. [More]
Tissue and cell diagnostics market reaches $7.7 billion in 2014

Tissue and cell diagnostics market reaches $7.7 billion in 2014

With fast and effective testing techniques, the tissue and cell diagnostics market was estimated to have reached $7.7 billion in 2014 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories, according to Kalorama Information. [More]
Techimmuna may help diagnose rheumatoid arthritis

Techimmuna may help diagnose rheumatoid arthritis

NCBJ POLATOM Radioisotope Centre has just introduced a new product to the nuclear medicine preparations market. Techimmuna will help to diagnose various cases of inflammation, in particular rheumatoid arthritis. [More]
R. Bryan Miller Symposium to spotlight special focus on rare disease research

R. Bryan Miller Symposium to spotlight special focus on rare disease research

The University of California, Davis Department of Chemistry will spotlight a special focus on rare disease research with this year's 15th annual R. Bryan Miller Symposium. Experts in rare diseases will gather at the UC Davis Conference Center March 5 for a conference highlighting the opportunities and challenges in applying cutting edge technologies and "precision medicine" to better treat conditions that together affect millions of people, especially children. [More]
Recipients of 2015 AACC and NACB Awards announced

Recipients of 2015 AACC and NACB Awards announced

AACC and its academy, the National Academy of Clinical Biochemistry, are pleased to announce the recipients of the 2015 AACC and NACB Awards, which honor laboratory medicine professionals worldwide for advancing the field of clinical laboratory testing. [More]
Great Basin Scientific begins clinical trial for Shiga toxin-producing E. coli diagnostic test

Great Basin Scientific begins clinical trial for Shiga toxin-producing E. coli diagnostic test

Great Basin Scientific, Inc., today announced it has initiated a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test. [More]
SRI Biosciences awarded contract to develop novel polymers to neutralize chemical, biological threats

SRI Biosciences awarded contract to develop novel polymers to neutralize chemical, biological threats

SRI Biosciences, a division of SRI International, has been awarded a $10 million contract under a DARPA program to reimagine how proteins are constructed and to develop novel medicines and diagnostics as countermeasures to chemical and biological threats. [More]

Henry Schein's net sales increase 7.0% to $2.7 billion in fourth quarter 2014

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record financial results for the fourth quarter. [More]
UM one step closer to developing potential drug for treating brain cancer

UM one step closer to developing potential drug for treating brain cancer

Promentis Pharmaceuticals, Inc. recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system. [More]
Blood gas POCT seminar video published online by sphere medical - new clinical resources centre added to sphere medical’s website

Blood gas POCT seminar video published online by sphere medical - new clinical resources centre added to sphere medical’s website

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, has published online a video of an industry seminar on ‘True Point-of-Care Testing’ presented by Dr. Tom Clutton-Brock, Senior Lecturer Anaesthesia and Intensive Care Medicine, University Hospital Birmingham at the AAGBI 2014 Annual Congress. [More]
Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Nanoparticle technology was originally developed in the 1980s and 1990s. As the technology evolved, it soon became possible to produce uniform nanoscopic beads that are magnetic, and that also have a variety of specific surface chemistries. It was immediately evident that such beads could be used to great advantage for biochemical separations. [More]

Alere reports net revenue of $666.9 million for fourth quarter 2014

Alere Inc., a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014. [More]
AirStrip, Batswadi announce strategic partnership to bring AirStrip products into Africa

AirStrip, Batswadi announce strategic partnership to bring AirStrip products into Africa

AirStrip and The Batswadi Group have announced a strategic partnership to bring the AirStrip ONE mobile interoperability platform and the Sense4Baby wireless fetal/maternal monitoring system into ten African countries, with an initial launch in South Africa. [More]
Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia. [More]